Drug Profile
Cangrelor - Chiesi Farmaceutici
Alternative Names: AR-C 69931; AR-C69931MX; CHF 6727; Kengreal; KengrexalLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer Chiesi Farmaceutici; Chiesi USA
- Class Adenine nucleotides; Antiplatelets; Phosphonic acids; Small molecules
- Mechanism of Action Platelet ADP receptor antagonists; Purinoceptor P2Y12 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Coronary artery disease; Coronary thrombosis
- No development reported Acute coronary syndromes
Most Recent Events
- 13 Nov 2020 Adverse events, pharmacokinetics and pharmacodynamics data from a phase I trial in Coronary thrombosis (In neonates, Prevention) presented at the American Heart Association (AHA-2020)
- 28 Feb 2020 No recent reports of development identified for phase-I development in Coronary-thrombosis(In neonates, Prevention) in USA (IV, Infusion)
- 23 Dec 2019 Chiesi Farmaceutici completes a phase I trial in Coronary thrombosis (In neonates, Prevention) in USA (IV) (NCT02765633)